Details

Autor(en) / Beteiligte

• Rosenthal, Emily W.
• Short, Vanessa L.
• Cruz, Yuri
• Barber, Cecily
• Baxter, Jason K.
• Abatemarco, Diane J.
• Roman, Amanda R.
• Hand, Dennis J.

Titel

Racial inequity in methadone dose at delivery in pregnant women with opioid use disorder

Ist Teil von

• Journal of substance abuse treatment, 2021-12, Vol.131, p.108454-108454, Article 108454

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Applied Social Sciences Index & Abstracts (ASSIA)

Beschreibungen/Notizen

• Medications for opioid use disorder, including methadone, combined with comprehensive wraparound services, are the gold standard for treatment in pregnancy. Higher methadone doses are associated with treatment retention in pregnancy and relapse prevention. Given known inequities where individuals of color tend to be prescribed lower doses of opioids for other conditions, the purpose of this study was to determine whether there is racial inequity in methadone dose at delivery in pregnant women with opioid use disorder. Retrospective review of medical charts identified pregnant women (N = 339) treated with methadone for opioid use disorder during pregnancy at one center from 2012 to 2017. Variables extracted from medical records included race, demographic and relevant clinical information (e.g., methadone dose at delivery, height, weight, etc.). Analyses used simple and multiple linear regressions to determine associations between these characteristics and methadone dose at delivery. The mean methadone doses at delivery among women of color and white women were 105.8 mg and 144.9 mg, respectively (p < .0001). After adjusting for maternal age, gestational age at delivery, body mass index, type of opioid used, and parity, race was significantly and independently associated with methadone dose at delivery, with women of color receiving 36.2 mg less than white women (p = .0003). Pregnant women of color with opioid use disorder received 67% of the dose of methadone at delivery that white women received. Antiracist responses to prevent provider bias in evaluating dose needs are needed to correct this inequity and prevent undertreatment of opioid use disorder among women of color. •Medication for Opioid Use Disorder, including methadone, is the gold standard for opioid use disorder in pregnancy.•Methadone dose in pregnant women is associated with treatment retention and substance use outcomes.•Pregnant women of color received lower doses of methadone at delivery as compared to white women, which reflects an inequity.